Evidence map›Paper›PMID 34515411›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022

Rates of longitudinal change in

Jeffrey S Phillips, Frederick J Nitchie, Fulvio Da Re, Christopher A Olm, Philip A Cook, Corey T McMillan, David J Irwin, James C Gee, Jacob G Dubroff, Murray Grossman and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Tau profiling across Alzheimer's disease staging reveals vulnerability to disease pathophysiology.European journal of nuclear medicine and molecular imaging · 2025
    Article
  7. Multi-parametric [European journal of nuclear medicine and molecular imaging · 2025
    Article
  8. Review
  9. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. A Visual Interpretation Algorithm for Assessing Brain Tauopathy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Rates of longitudinal change inAlzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jeffrey S PhillipsUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0079-9441
Frederick J NitchieUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Fulvio Da ReUniversity of Milan-Bicocca Faculty of Medicine and Surgery, Universita degli Studi di Milano-Bicocca Dipartimento di Medicina e Chirurgia, Milan, Italy.
Christopher A OlmUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Philip A CookUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Corey T McMillanUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
David J IrwinUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
James C GeeUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jacob G DubroffUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Murray GrossmanUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ilya M NasrallahUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Alzheimer's Disease Neuroimaging Initiative
University of Pennsylvania · USAlzheimer’s Disease Neuroimaging Initiative · USUniversity of Milano-Bicocca · IT

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Laurel A Beckett · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Ultrascale Machine Learning to Empower Discovery in Alzheimers Disease BiobanksU01AG068057 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Christos Davatzikos, Heng Huang · 2020 to 2026
$20.7M
Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Marka Van Blitterswijk · 2014 to 2026
$19.8M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
Spreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4M
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's diseaseR01AG063888 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SMALL, SCOTT A · 2020 to 2024
$4.8M
Biological Aging Contributions to Molecular Pathology and NeurodegenerationR01AG066152 · NIA · UNIVERSITY OF PENNSYLVANIA · PI MCMILLAN, COREY T · 2019 to 2023
$3.8M
Microscopic and Large-Scale Networks of Molecular Pathology in Frontotemporal Lobar DegenerationR01NS109260 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI IRWIN, DAVID JOHN · 2019 to 2023
$3.8M
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)U01NS107027 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BENATAR, MICHAEL, MALASPINA, ANDREA · 2018 to 2023
$3.5M
NIA NIH HHS K01 AG061277NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG054519NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG063888NIA NIH HHS R01 AG066152NIA NIH HHS R56 AG058732NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG068057NIA NIH HHS U19 AG024904NIDA NIH HHS K23 DA038726NINDS NIH HHS R01 NS109260NINDS NIH HHS U01 NS107027NINDS NIH HHS U54 NS092091
6 · The paper itself

Abstract

introductionLongitudinal positron emission tomography (PET) studies of tau accumulation in Alzheimer's disease (AD) have noted reduced increases or frank decreases in tau signal. We investigated how such reductions related to analytical confounds and disease progression markers in atypical AD.

methodsWe assessed regional and interindividual variation in longitudinal change on

resultsIn atypical AD, DISCUSSION: Results suggested radioligand uptake plateaus or declines in advanced neurodegeneration. Further research should investigate whether results generalize to other radioligands and whether they relate to changes of the radioligand binding site structure or accessibility.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBrainCarbolinesHumansPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloid beta-PeptidesCarbolinestau Proteinsatypical Alzheimer's diseaseflortaucipirlogopenic-variant primary progressive aphasialongitudinalnon-amnestic Alzheimer's diseasepositron emission tomographyposterior cortical atrophytau

Identifiers

PMID34515411
PMCPMC9292954
OpenAlexW3201347845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.